Reduction of recombinant human erythropoietin maintenance dose by supplementation with a low-dose iron preparation, given intravenously

Clinical and Experimental Nephrology

Volumn 5, Issue 4, 2001, Pages 228-233

  Mitsuiki, K ^a   Harada, A ^a   Miyata, Y ^a  

^a MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

Chondroitin sulfate iron colloid; Erythropoietin; Hemodialysis; Iron deficiency

Indexed keywords

CHONDROITIN SULFATE IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; ECONOMIC ASPECT; FEMALE; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; IRON THERAPY; JAPAN; MAINTENANCE THERAPY; MALE;

EID: 0035702844     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-001-8018-z     Document Type: Article

References (10)

1. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation
2. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients
3. Achieving target hematocrit in dialysis patients: New concepts in iron management
4. Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients
5. Importance of iron supply for erythropoietin therapy
6. The safety of intravenous iron dextran in hemodialysis patients
7. Experience with i.v. iron chondroitin-sulphate colloid in Japanese haemodialysis patients
8. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
9. European best practice guidelines for the management of anaemia in patients with chronic renal failure
10. Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in crythropoietin-treated patients